Byfavo 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification0F
Decision 
Information 
1 issued on 
Issued1F
2 / 
affected2F
3  
amended 
on 
IB/0014/G 
This was an application for a group of variations. 
15/06/2023 
SmPC 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
B.II.f.1.e - Stability of FP - Change to an approved 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
stability protocol 
B.II.e.7.b - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
IB/0015/G 
This was an application for a group of variations. 
31/05/2023 
n/a 
B.II.f.z - Stability of FP - Other variation 
B.II.f.1.e - Stability of FP - Change to an approved 
stability protocol 
IAIN/0013/G 
This was an application for a group of variations. 
17/04/2023 
Annex II and 
PL 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0011 
B.II.f.z - Stability of FP - Other variation 
12/04/2023 
n/a 
X/0002 
Annex I_2.(c) Change or addition of a new 
26/01/2023 
31/03/2023 
SmPC, 
strength/potency 
Annex I_2.(d) Change or addition of a new 
pharmaceutical form 
Labelling and 
PL 
Page 2/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0010 
B.II.b.1.a - Replacement or addition of a 
14/02/2023 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IAIN/0009 
B.II.b.2.c.1 - Change to importer, batch release 
14/02/2023 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
PSUSA/10924
Periodic Safety Update EU Single assessment - 
09/02/2023 
n/a 
PRAC Recommendation - maintenance 
/202207 
remimazolam 
IB/0008/G 
This was an application for a group of variations. 
10/01/2023 
n/a 
B.I.d.1.b.3 - Stability of AS - Change in the storage 
conditions - Change in storage conditions of the AS 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.d.1.z - Stability of AS - Change in the re-test 
period/storage period or storage conditions - Other 
variation 
Page 3/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
PSUSA/10924
Periodic Safety Update EU Single assessment - 
15/09/2022 
18/11/2022 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/202201 
remimazolam 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10924/202201. 
T/0006 
Transfer of Marketing Authorisation 
21/09/2022 
07/10/2022 
SmPC, 
IA/0005/G 
This was an application for a group of variations. 
06/07/2022 
n/a 
Labelling and 
PL 
B.II.c.2.a - Change in test procedure for an excipient 
- Minor changes to an approved test procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
IA/0004/G 
This was an application for a group of variations. 
24/06/2022 
n/a 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
Page 4/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10924
Periodic Safety Update EU Single assessment - 
24/02/2022 
25/04/2022 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/202107 
remimazolam 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10924/202107. 
Page 5/5 
 
 
 
 
 
 
 
